Nanosphere's Revenues Double as Firm Names New CEO; Stock Plummets | GenomeWeb

NEW YORK (GenomeWeb News) – Nanosphere reported after the close of the market Wednesday that its full-year revenues more than doubled and it trimmed its annual loss.

The firm also announced a management shakeup, which includes the naming of a new CEO and the replacement of several board members. Wall Street reacted negatively to the changes and a revenue forecast below expectations, sending the firm's shares tumbling 30 percent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.